This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Expanding the potential patient population for pulsed field ablation, results from the SINGLE SHOT CHAMPION study suggest PFA might be just as good as cryoballoon ablation for patients with paroxysmal AFib. Atrial tachyarrhythmia recurred in 37.1% The post PFA or Cryoballoon for Paroxysmal AFib?
(MedPage Today) -- LONDON -- Pulmonary vein isolation (PVI) produced real short-term improvements for people with atrialfibrillation (Afib or AF), according to the first sham-controlled trial on the subject. Continuous monitoring by implantable.
(MedPage Today) -- The FDA approved the Farapulse pulsed field ablation (PFA) system for paroxysmal atrialfibrillation (Afib or AF), Boston Scientific announced on Wednesday. The device won an indication for the isolation of pulmonary veins in.
The international, multi-center trial will provide clinical evaluation of Cortex's 510(k) cleared Ablamap System with electrographic flow (EGF) and newly released Ablacath Mapping Catheter basket mapping catheter to identify extra-pulmonary vein EGF sources.
male with pertinent past medical history including Atrialfibrillation, atrial flutter, cardiomyopathy, Pulmonary Embolism, and hypertension presented to the Emergency Department via ambulance for respiratory distress and tachycardia. Bedside ultrasound showed volume depletion and no pulmonary edema.
Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy AtrialFibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. 2,3 Approximately 1 in 4 adults over the age of 40 are at risk for developing AFib.4 In: AF Symposium.; February 2-4; Boston.
The AFib pulsed field ablation treatment era officially began in the US last week, following the FDA approval of Medtronic’s PulseSelect Pulsed Field Ablation System for the treatment of both paroxysmal and persistent atrialfibrillation. At 1 year, the PulseSelect PFA was also clinically effective among 66.2%
Compared with a sham procedure, pulmonary vein isolation resulted in a statistically significant and clinically important decrease in atrialfibrillation (AFib) burden at six months, according to results from the SHAM-PVI trial presented at ESC Congress 2024 in London and simultaneously published in JAMA.
Patients undergoing atrialfibrillation (AFib) ablation who were not properly anticoagulated and did not undergo preprocedural transesophageal echocardiogram (TEE) were significantly more likely to suffer from transient ischemic attack (TIA) or pulmonary embolism (PE).
Performing additional catheter ablations targeting diseased myocardium along with the standard approach of pulmonary vein isolation (PVI) to treat persistent atrialfibrillation (AFib) did not reduce the recurrence of AFib at one year, based on findings from the SUPPRESS-AF trial presented at ESC Congress 2024 in London.
Food and Drug Administration (FDA) has approved the FARAPULSE Pulsed Field Ablation System for isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, paroxysmal atrialfibrillation (AFib), according to a Boston Scientific press release.
SmartPulse is a prospective, single arm, multi-center, clinical evaluation that will enroll approximately 250 patients with paroxysmal AFib in the United States to evaluate the safety and effectiveness of the Dual Energy STSF Catheter. “ The SmartPulse pivotal trial will allow us to learn more about the promise of PFA in paroxysmal AFib.
Here is the computer interpretation: ATRIALFIBRILLATION WITH RAPID VENTRICULAR RESPONSE WITH ABERRANT CONDUCTION OR VENTRICULAR PREMATURE COMPLEXES LEFT AXIS DEVIATION [QRS AXIS beyone -30] NONSPECIFIC ST and T-WAVE ABNORMALITY The over-reading physician confirmed this diagnosis, which is incorrect. It is not atrialfibrillation.
This middle-aged patient presented with SOB, weakness, and mild pulmonary edema. She previously had Atrialfibrillation with LBBB. This shows atrialfibrillation. The fact that the response is regular proves that the atrialfibrillation is NOT conducting. There is a regular, slow response.
Prognostic impact of severe tricuspid regurgitation (TR) in patients with atrial functional mitral regurgitation (AFMR). Patients with severe TR were older, mostly with atrialfibrillation, and had more severe heart failure symptoms and more advanced left atrial and right heart remodelling than those with non-severe TR.
Atrialfibrillation is also a predictor of worse outcomes in this case (Alborzi). Q waves in association with RBBB are usually not seen in anterior leads unless there is pulmonary hypertension or anterior infarction. Other Arrhythmias ( PACs, PVCs, AFib, Bradycardia and AV conduction disorders — potentially lethal VT/VFib ).
The rhythm appears to be atrialfibrillation. An old formal echo was found from 6 mo ago: Dilated right ventricle with septal flattening and estimated right ventricular systolic pressure of 70 mmHg (significant pulmonary hypertension). This was texted to me. An 80-something woman who presented with chest pain and dyspnea.
The VARIPULSE Platform is designed to enable pulmonary vein isolation with the versatility of a catheter loop, a simple generator user interface, and a mapping system that provides an intuitive, reproducible workflow with real-time visualization, contact indicator, and PF tagging mechanisms. In the U.S.,
The collaboration, according to a written statement issued by the company, aims to address challenges in capturing and analyzing cardiac signals to help physicians enhance patient outcomes for atrialfibrillation procedures. 1 Approximately 33 million patients worldwide are living with AFib.
During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrialfibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.
tim.hodson Thu, 03/27/2025 - 12:18 March 27, 2025 Abbott recently announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrialfibrillation (AFib). Today, approximately 8 million Europeans over the age of 65 are living with AFib, a number expected to double over the next 30 years.
The pipeline of algorithms likely to clear regulatory hurdles and enter the cardiac market over the next 12-18 months include those for Pulmonary Hypertension, Cardiac Amyloidosis, Diastolic dysfunction, and Hyperkalaemia. Fertile Partnerships Ongoing research partnerships have driven much of recent developments seen in the market.
(Harvard University Heart Letter) A clinical polygenic risk score test for diseases ranging from atrialfibrillation (AFib) to breast cancer was piloted by scientists. JACC: Asia) Lexaria Bioscience has announced that a CBD product beats a placebo in simulating acute pulmonary hypertension.
The rhythm is atrialfibrillation. The morphology of V2-V4 is very specific in my experience for acute right heart strain (which has many potential etiologies, but none more common and important in EM than acute pulmonary embolism). CT angiogram showed extensive saddle pulmonary embolism.
Boston Scientific made what could become a major addition to its electrophysiology portfolio, acquiring AFib mapping startup Cortex, Inc. Cortex gives Boston Scientific a new mapping technology that detects AFib signs and triggers outside of the pulmonary veins, and can help EP teams develop ablation strategies for more complex AFib cases.
With this approval, Medtronic now offers two PFA technologies available for patients with Afib. With a short learning curve for experienced physicians, the possibilities are boundless for the treatment of Afib," said Vivek Reddy, M.D., tim.hodson Wed, 10/30/2024 - 13:42 Oct.
New science presented at AHA 2024 and simultaneously published in JACC: Advances provide insights on emerging topics such as the use of artificial intelligence (AI)-enabled left atrial (LA) volumetry in coronary artery calcium (CAC) scans to predict atrialfibrillation (AFib); the role of treating hospitals in facilitating cardiac rehabilitation (CR); (..)
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content